Do learn the difference between an algorithm and AI. The usual incorrect negative reply. You allegedly hold RCE. But you bag it as often as the other resident troll. Chris Kallos, CFA, Senior Analyst, is all over the report as the author.
Whilst anyone with a brain would take the $2.62 valuation with a large grain of salt (and similarly Recce's potential approval and commercial R327G Indonesian launch of 1HCY26 - no way that happens before 2HCY26), some very useful professional evaluation of RCE's future and a little insight into some of yesterday's buying (perhaps a few MST clients). Thanks
@Karritree for providing the report. MST clearly takes Graham's optimism on the speed of commercial revenues with a healthy dose of scepticism, but surprisingly still comes up with a massive upside valuation, clearly on >2027 revenue and earning expectations in Sepsis particularly. Its a shame we cannot see those discounted future cash flows through to 2037 that they use to come up with their $754 million valuation.
The report, even taken with a healthy dose of scepticism, provides a very good summary of RCE's business and prospects. Investors (and resident trolls) really have no excuse to be uninformed on the company, but the trolls already showing they still will with aimless comments.
I am a little more optimistic than MST on both the peak and emergence of early significant cash flows from Indo' DFI sales revenue, but not unsurprisingly, with a very healthy risk discount of 15% execution likelihood applied, Sepsis is where it is at for MST - I am also more optimistic on likelihood of approval and execution of Indo' DFI at 40% (the trolls with their one liners never get that most investors have a very healthy risk of execution discount applied to Graham and co., well aware of their shortcomings, but still consider RCE a good, if risky investment at such a low valuation).
Conversely, I am a little less optimistic on the Sepsis launch, and a little more optimistic on a US DFI launch date (late 2028 maybe) under emerging developments at the FDA on the speed of regulatory advancement of 'national health priority' approvals (from the truncated process used to authorize the first COVID-19 vaccines under Operation Warp Speed) and a possible pathway under the new "national priority vouchers" scheme to be offered to companies "aligned with U.S. national priorities".
GLTA(genuine)H - its been a horrible journey in RCE for most long term shareholders after all.
(20min delay)